Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee

Exclusion Criteria

• •1. History or presence at the screening visit of non-OA inflammatory joint disease (eg, rheumatoid arthritis, lupus erythematosus, psoriatic arthritis, pseudo-gout, gout, spondyloarthropathy, polymyalgia rheumatica, joint infections within the past 5 years), Paget's disease of the spine, pelvis or femur, neuropathic disorders, multiple sclerosis, fibromyalgia, tumors or infections of the spinal cord, or renal osteodystrophy
• •2. History or presence on imaging of arthropathy (osteonecrosis, subchondral insufficiency fracture, rapidly progressive OA type 1 or type 2), stress fracture, recent stress fracture, neuropathic joint arthropathy, hip dislocation (prosthetic hip dislocation is eligible), knee dislocation (patella dislocation is eligible), congenital hip dysplasia with degenerative joint disease, extensive subchondral cysts, evidence of bone fragmentation or collapse, or primary metastatic tumor with the exception of chondromas or pathologic fractures during the screening period
• •3. Trauma to the index joint within 3 months prior to the screening visit
• •4. History or presence of signs or symptoms of compression neuropathy, including carpal tunnel syndrome or sciatica
• •5. Participant is not a candidate for Magnetic Resonance Imaging (MRI)
• •6. Poorly controlled diabetes
• •7. Known history of human immunodeficiency virus (HIV) infection
• •8. Known history of ocular herpes simplex virus, herpes simplex virus pneumonia, or herpes simplex virus encephalitis
• •9. History of poorly controlled hypertension
• •10. Known history of infection with hepatitis B or C virus
• •Note: Other protocol defined Inclusion/Exclusion apply